Coenzyme Q10 alleviates silicotic fibrosis in rats through the TGF-β1/Smad pathway
Frontiers in Pharmacology · 15.04.2026 · 17
DOI: 10.3389/fphar.2026.1821205 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 15.04.2026. Verfasst von Jiping Yi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Prevention and Treatment Institute for Occupational Diseases, Affiliated Prevention and Treatment Institute for Occupational Diseases of Univer…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Silicosis, the most prevalent occupational disease worldwide, currently lacks effective clinical treatments. Therefore, identifying an effective intervention and preventive drug is crucial for inhibiting silicosis fibrosis. Our preliminary experiments suggested that coenzyme Q10 (CoQ10) may alleviate fibrosis in a rat silicosis model, but the underlying mechanism remains unclear.
Methods
In this study, a rat silicosis model was established via a single tracheal instillation of SiO 2 dust suspension. Rats were then treated with CoQ10 at doses of 20, 50, and 125 mg/kg/d to investigate its mechanism in improving silica-induced inflammation and fibrosis.
Results
Results showed that CoQ10 significantly reduced levels of inflammatory cytokines IL-1β and TNF-α in bronchoalveolar lavage fluid (BALF), alleviated lung tissue inflammation, oxidative stress, and collagen deposition. In the medium- and high-dose CoQ10 groups, expression of fibrosis-related proteins (α-SMA, Vimentin, Col-I, Col-III) decreased, while E-cad expression increased. Moreover, expression of TGF-β1, Smad2, and Smad3 was downregulated, and Smad7 expression was upregulated.
Conclusion
These findings suggest that the anti-fibrotic effect of CoQ10 on silicosis may be associated with reducing pulmonary inflammation and oxidative stress, thereby inhibiting the TGF-β1/Smad signaling pathway. This study provides new insights into understanding the pathogenesis and potential treatment of silicosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hunan Prevention and Treatment Institute for Occupational Diseases, Affiliated Prevention and Treatment Institute for Occupational Diseases of University of South China, Changsha, China.
- Nanchang Railway Disease Control and Prevention Institute, China Railway Nanchang Group Co., Ltd., Nanchang, China.
- Department of Health Toxicology, Xiangya School of Public Health, Central South University, Changsha, China.
Zitieren
APA
Yi, J., Wang, Y., Zhang, H., Yang, X., Xiong, T., Xie, H., Zhan, L., & Zeng, M. (2026). Coenzyme Q10 alleviates silicotic fibrosis in rats through the TGF-β1/Smad pathway. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1821205
Vancouver
Yi J, Wang Y, Zhang H, Yang X, Xiong T, Xie H, et al. Coenzyme Q10 alleviates silicotic fibrosis in rats through the TGF-β1/Smad pathway. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1821205
BibTeX
@article{Yi2026,
author = {Yi, Jiping and Wang, Yougen and Zhang, Hualing and Yang, Xiuhong and Xiong, Tianci and Xie, Huanhuan and Zhan, Lichao and Zeng, Ming},
title = {Coenzyme Q10 alleviates silicotic fibrosis in rats through the TGF-β1/Smad pathway},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1821205}
}
EUVIMED